Pros | Among most bought funds within the category. Larger AUM within category. Beats FD returns for both 3Y & 5Y duration. | 3Y returns in the top 25% of the category. Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | 6/8 | 4/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 11 Years | 11 Years | ||
Fund Size | 8648 Cr | 3203 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹500 Lumpsum ₹5000 | ||
Expense Ratio | 0.9% | 0.9% | ||
Exit Load | 1% | 0.5% | ||
Benchmark Index | S&P BSE Healthcare PR | S&P BSE Healthcare PR |
No of Holdings | 36 | 31 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (13.81%) Lupin Ltd (8.3%) Divi's Laboratories Ltd (7.96%) Cipla Ltd (5.93%) Dr Reddy's Laboratories Ltd (5.69%) | Sun Pharmaceuticals Industries Ltd (11.94%) Divi's Laboratories Ltd (5.73%) Lupin Ltd (5.6%) Max Healthcare Institute Ltd Ordinary Shares (5.44%) Cipla Ltd (5.17%) | ||
No of Sectors | 1 | 2 | ||
Top 3 Sectors | Health (100%) | Health (93.61%) Basic Materials (6.39%) | ||
Equity % | 97.4% | 96.24% | ||
Debt % | - | - | ||
P/E | 41.81 | 48.92 | ||
P/B | 7.11 | 7.22 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.77% | 3.19% | ||
3-Month Return | 17.19% | 17.69% | ||
6-Month Return | 20.94% | 22.26% | ||
1-Year Return | 49.55% | 51.54% | ||
3-Year Return | 20.1% | 22.83% | ||
5-Year Return | 31.45% | 32.94% |
Sharpe | 0.93 | 1.09 | ||
Alpha | 1.36 | 3.76 | ||
Beta | 0.91 | 0.89 | ||
Standard Deviation | 15.19 | 14.82 | ||
Information Ratio | 0.12 | 0.74 |
Description | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Kinjal Desai,Sailesh Raj Bhan | Mohit Jain,Tanmaya Desai |